Gossamer bio announces addition of two cns-penetrant btk inhibitors to its product candidate pipeline: gb5121 & gb7208

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the addition of two cns-penetrant bruton's tyrosine kinase (btk) inhibitors to its product candidate pipeline. gossamer plans to initiate first-in-human studies of the first of these candidates, gb5121, in the fourth quarter of 2021. g
GOSS Ratings Summary
GOSS Quant Ranking